The U.S. Centers for Disease Control and Prevention (CDC) has reported more than 60 laboratory-confirmed Clade I mpox cases across at least 20 states, with an increasing share of cases since August occurring among individuals with no recent international travel or known links to travelers. Presumed domestic transmission has been identified in more than 10 jurisdictions, leading the CDC to describe a “likely transition to sustained Clade Ib transmission in the United States.” While the agency continues to assess the risk to the general population as low, the shift marks a significant change in the epidemiology of mpox in the country and carries implications for public health preparedness.
GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines against infectious diseases and therapies for solid tumor cancers, highlighted the CDC’s September 25 update as evidence that preparedness efforts must anticipate changes in transmission rather than react to them. David Dodd, Chairman and CEO of GeoVax, said, “CDC’s latest assessment represents an important change in the epidemiology of Clade Ib mpox in the United States. While the risk to the general population remains low, presumed domestic transmission across multiple jurisdictions reinforces the importance of continued surveillance, vaccination of appropriate at-risk populations and sustained preparedness.”
The development is notable because the 2022 global mpox outbreak, including the large U.S. outbreak, was caused by Clade IIb. Clade I mpox has historically been associated with more severe disease and higher mortality than Clade II, although severity varies by subclade, population, and access to medical care. Recent Clade Ib cases in high-income countries have generally involved relatively mild illness. The significance of the CDC’s assessment therefore extends beyond disease severity alone; it represents an important change in the geographic footprint and transmission dynamics of mpox in the United States. As recently as August, the CDC reported that sustained Clade Ib transmission had not been detected in the U.S. during 2024–2025. The September 25 assessment now indicates a likely transition toward sustained domestic transmission.
Globally, Clade I outbreaks have continued in Central and Eastern Africa since late 2023, with subsequent geographic expansion, including transmission in parts of Europe and introductions into the United States. This evolving epidemiology follows other recent public-health actions, such as updated CDC vaccination recommendations for certain U.S. travelers at increased risk and international initiatives to strengthen access to mpox vaccines and outbreak-response capabilities.
GeoVax is developing GEO-MVA, a Modified Vaccinia Ankara (MVA)-based vaccine for protection against mpox and smallpox. Following formal guidance from the European Medicines Agency, the company is advancing GEO-MVA through an expedited clinical development pathway, with traditional Phase 1 and Phase 2 trials not required. GeoVax expects to initiate a 500-participant pivotal Phase 3 immunobridging study in the fourth quarter of 2026, with results expected in mid-2027. The company believes GEO-MVA can become a strategic preparedness asset by supporting diversified vaccine supply, scalable manufacturing capacity, and greater supply resilience.
Dodd added, “Preparedness should not begin when an infectious-disease threat becomes a crisis. The appropriate time to strengthen vaccine capacity, diversify sources of supply and establish scalable manufacturing infrastructure is before those capabilities are urgently needed.” He concluded, “Low risk to the general population today and the need for long-term preparedness are not contradictory. CDC’s latest assessment illustrates why preparedness must anticipate changes in infectious-disease transmission rather than react to them after they occur.” For more information, visit www.geovax.com. This news was originally distributed by NEWMEDIAWIRE.
